Previous close | 131.86 |
Open | 131.40 |
Bid | 131.86 x 100 |
Ask | 132.85 x 100 |
Day's range | 131.40 - 136.00 |
52-week range | 131.28 - 266.67 |
Volume | |
Avg. volume | 255,017 |
Market cap | 14.771B |
Beta (5Y monthly) | 0.63 |
PE ratio (TTM) | N/A |
EPS (TTM) | -8.45 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 272.77 |
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., March 14, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr) as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. TEVIMBRA will be available in the U.S. in t